# Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC

> **NCT06768255** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Ding-Wei Ye** · enrollment: 400 (estimated)

## Conditions studied

- Abiraterone Acetate
- MCRPC (metastatic Castration-resistant Prostate Cancer)

## Interventions

- **DRUG:** Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT
- **DRUG:** Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT

## Key facts

- **NCT ID:** NCT06768255
- **Lead sponsor:** Ding-Wei Ye
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-30
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06768255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06768255, "Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06768255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*